We are live on
!
Find out more
HA
HC Advisors Portfolio holdings
AUM
$149M
1-Year Est. Return
17.72%
This Fund
S&P 500
This Quarter
Est. Return
-3.27%
1 Year Est. Return
+17.72%
3 Year Est. Return
+55.19%
5 Year Est. Return
+59.33%
10 Year Est. Return
–
AUM
$145M
AUM Growth
+$4.81M
(+3.4%)
Cap. Flow
+$12.4M
Cap. Flow
% of AUM
8.52%
Top 10 Holdings %
Top 10 Hldgs %
55.1%
Holding
87
New
7
Increased
40
Reduced
15
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRISPR Therapeutics
CRSP
|
+$3.37M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$2.02M |
| 3 |
iShares US Financials ETF
IYF
|
+$1.51M |
| 4 |
Vanguard Energy ETF
VDE
|
+$1.31M |
| 5 |
SCHR
Schwab Intermediately-Term US Treasury ETF
SCHR
|
+$904K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.29M |
| 2 |
Schwab Short-Term US Treasury ETF
SCHO
|
+$487K |
| 3 |
Vanguard Russell 1000 Value ETF
VONV
|
+$281K |
| 4 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$265K |
| 5 |
ExxonMobil
XOM
|
+$215K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 7.38% |
| 2 | Technology | 2.82% |
| 3 | Financials | 1.9% |
| 4 | Industrials | 1.05% |
| 5 | Consumer Discretionary | 0.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Agnico Eagle Mines
AEM
$75.4B
| $199K | 0.14% |
+4,721
| New | +$202K |
|
77
Dyne Therapeutics
DYN
$4.8B
| $181K | 0.12% |
14,272
-1,155
| -7% | -$13.2K |
|
|
NGD
78
DELISTED
New Gold Inc
NGD
| $181K | 0.12% |
205,750
+28,200
| +16% | +$22.3K |
|
79
Alamos Gold
AGI
$11.9B
| $165K | 0.11% |
+22,250
| New | +$165K |
|
80
ALX Oncology
ALXO
$262M
| $133K | 0.09% |
13,933
-190
| -1% | -$2.21K |
|
81
Norwegian Cruise Line
NCLH
$8.59B
| $114K | 0.08% |
10,000
| – | – |
|
|
MTTR
82
DELISTED
Matterport, Inc. Class A Common Stock
MTTR
| $114K | 0.08% |
30,000
| – | – |
|
83
TG Therapeutics
TGTX
$8.19B
| $68K | 0.05% |
+11,500
| New | +$75.4K |
|
|
TINV.WS
84
DELISTED
Tiga Acquisition Corp. Warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
TINV.WS
| $55K | 0.04% |
80,391
| – | – |
|
85
Akebia Therapeutics
AKBA
$362M
| $3K | ﹤0.01% |
+10,000
| New | +$3.92K |
|
86
Alphabet (Google) Class A
GOOGL
$4.08T
| – | – |
-1,820
| Closed | -$198K |
|
|
87
ExxonMobil
XOM
$651B
| – | – |
-2,506
| Closed | -$215K |
|
Similar funds
ZC
LGM
SWM
AWF
AIA
TWM
E
GWA
HC Advisors's Q3 2022 Portfolio in Review
As of Q3 2022, HC Advisors held 87 positions worth $145M, up 3.4% from $140M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
HC Advisors deployed $12.4M of net new capital in Q3 2022, opening 7 new positions and adding to 40 existing holdings. Its largest new stake was Zeta Global: 132,789 shares worth $878K.
By sector, the portfolio is most concentrated in Healthcare at 7.4% of assets, up from 3.2% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Apple, an estimated $1.29M trimmed.
- HC Advisors's largest Q3 2022 buy was Zeta Global: 132,789 shares worth $878K.
- HC Advisors added most to CRISPR Therapeutics in Q3 2022, an estimated $3.37M increase.
- HC Advisors's biggest Q3 2022 reduction was Apple, cutting an estimated $1.29M.
- HC Advisors fully exited ExxonMobil in Q3 2022, selling an estimated $215K.
- HC Advisors's ten largest holdings make up 55% of its $145M portfolio in Q3 2022.
- HC Advisors opened 7 new positions and closed 2 in Q3 2022.
- HC Advisors's portfolio value rose 3.4% quarter-over-quarter to $145M.
Based on HC Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.